Institutional members access full text with Ovid®

Share this article on:

TOPICAL NEPAFENAC AFTER INTRAVITREAL INJECTION: A Prospective Double-Masked Randomized Controlled Trial

Ulrich, J. Niklas MD

doi: 10.1097/IAE.0b013e3182a0e611
Original Study

Purpose: To evaluate if a single drop of nepafenac can reduce the ocular discomfort after intravitreal injections compared with placebo.

Methods: One hundred and twenty patients undergoing intravitreal injections of bevacizumab or ranibizumab received a drop of nepafenac or placebo (Systane Ultra) after the injection in a prospective, double-masked, randomized controlled design. Patients rated their pain levels from 0 to 3 (no pain, mild pain, moderate pain, severe pain) at 1 hour, 6 hours, and 24 hours after the procedure.

Results: Statistically significant reduction of postinjection pain with nepafenac was noted 6 hours after the injection when compared with placebo (0.8 ± 0.6 [standard deviation] vs. 1.3 ± 0.8, P < 0.001) with similar trends at 1 hour (1.1 ± 0.7 vs. 1.3 ± 0.7, P = 0.12) and 24 hours (0.3 ± 0.5 vs. 0.5 ± 0.6, P = 0.15).

Conclusion: A single drop of nepafenac is effective in reducing discomfort after intravitreal injections.

This prospective, double-masked, randomized controlled study suggests that a single drop of nepafenac is more effective in reducing discomfort after intravitreal injections than placebo (Systane Ultra).

Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina.

Reprint requests: J. Niklas Ulrich, MD, Department of Ophthalmology, University of North Carolina, 5151 Bioinformatics Building, CB 7040, Chapel Hill, NC 27599-7040; e-mail: jnulrich@med.unc.edu

Supported by an unrestricted grant from Research to Prevent Blindness.

The author has no conflicting interests to disclose.

© 2014 by Ophthalmic Communications Society, Inc.